Holen Sie sich die Stockscreener-App
8.505
8.04%
0.685
Schlusskurs vom Vortag:
$7.82
Offen:
$8.21
24-Stunden-Volumen:
11.58M
Relative Volume:
0.34
Marktkapitalisierung:
$8.75B
Einnahmen:
$113.29M
Nettoeinkommen (Verlust:
$-351.47M
KGV:
-21.82
EPS:
-0.3898
Netto-Cashflow:
$-309.19M
1W Leistung:
-2.55%
1M Leistung:
+42.12%
6M Leistung:
+224.95%
1J Leistung:
+191.34%
1-Tages-Spanne:
$8.20
$8.66
1-Wochen-Bereich:
$7.77
$8.7899
52-Wochen-Spanne:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Firmenname
Immunitybio Inc
Sektor
Branche
Telefon
(844) 696-5235
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.515 | 8.04B | 113.29M | -351.47M | -309.19M | -0.3898 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.00 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.24 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
701.00 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.99 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.45 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | BTIG Research | Buy |
| 2023-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Eingeleitet | Jefferies | Buy |
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell? - Zacks Investment Research
ImmunityBio completes NK cell manufacturing programs - Investing.com
Single apheresis yields 5B NK cells in ImmunityBio cancer program - Stock Titan
Why ImmunityBio Stock Is Soaring Today - AOL.com
ImmunityBio’s (IBRX) Bladder Cancer sBLA Resubmission Tests The Depth Of Its Immuno‑Oncology Strategy - simplywall.st
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Assessing ImmunityBio (IBRX) Valuation After FDA Acknowledges Resubmitted ANKTIVA Bladder Cancer Filing - simplywall.st
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.2%What's Next? - MarketBeat
Immunitybio stock initiated at Buy by BTIG with $13 target - Investing.com
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga
IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst - Stocktwits
IBRX Stock Falls -23% In 6-Day Spree On Profit-Taking After 500% YTD Gain - Trefis
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact - Stocktwits
ImmunityBio Earnings Call: ANKTIVA Surge Amid High Burn - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio Faces Potential Setback Amid Director’s Share Sale and Investigation - timothysykes.com
ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - marketscreener.com
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge - simplywall.st
FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story - Yahoo Finance
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) - Finviz
IBRX stock declines — ImmunityBio resubmits Anktiva application to FDA with additional data - MSN
ImmunityBio (NASDAQ:IBRX) Shares Down 2.5%Should You Sell? - MarketBeat
ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews - Stocktwits
Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga
IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug - Bitget
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data - The Malaysian Reserve
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Asianet Newsable
ImmunityBio Stock Sinks as FDA Review Drags On - TipRanks
ImmunityBio resubmits bladder cancer application to FDA - Investing.com
ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG - TipRanks
FDA seeks more bladder cancer data; ImmunityBio resubmits ANKTIVA bid - Stock Titan
ImmunityBio’s Stock Sees a Huge Boost - Los Angeles Business Journal
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN
How dovish Fed policy supports ImmunityBio Inc. (26CA) stock2026 Technicals & Weekly Market Pulse Alerts - Naître et grandir
ImmunityBio (IBRX) soars to new high on Anktiva future expansion - MSN
Vanguard Group Inc. Boosts Stock Position in ImmunityBio, Inc. $IBRX - MarketBeat
How ImmunityBio Inc. stock valuations compare to rivalsJuly 2025 Drop Watch & Fast Entry High Yield Tips - Naître et grandir
Rafferty Asset Management LLC Grows Stake in ImmunityBio, Inc. $IBRX - MarketBeat
ImmunityBio (NASDAQ:IBRX) Trading Down 3.2%Time to Sell? - MarketBeat
H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating - Bitget
ImmunityBio ANKTIVA Milestones Reshape Growth Outlook And Risk Profile - Sahm
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11% - Stocktwits
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies - Yahoo Finance
ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout - Yahoo Finance
ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses - Yahoo Finance
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Piper Sandler Maintains Overweight on ImmunityBio (IBRX) March 2026 - Meyka
Finanzdaten der Immunitybio Inc-Aktie (IBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):